This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

Lower risk for foot disease driven by lower risk for neuropathy for new users of SGLT-2 inhibitors versus GLP-1 receptor agonists ...

SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause mortality ...

Please provide your email address to receive an email when new articles are posted on . Most patients who qualify for an SGLT2 inhibitor are not prescribed one. Prescription rates for those with a ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of sodium-glucose cotransporter 2 inhibitors was ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...